Navigation Links
Cimzia® (certolizumab pegol) Data Showed Broad and Rapid Relief From Burden of Symptoms In Rheumatoid Arthritis Patients
Date:5/10/2011

er infections due to opportunistic pathogens.

The risks and benefits of treatment with certolizumab pegol should be carefully considered prior to initiating therapy in patients with chronic or recurrent infection.  Patients should be closely monitored for the development of signs and symptoms of infection during and after treatment with certolizumab pegol, including the possible development of tuberculosis in patients who tested negative for latent tuberculosis infection prior to initiating therapy.

Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with TNF blockers, of which certolizumab pegol is a member.  Certolizumab pegol is not indicated for use in pediatric patients.

Serious and sometimes fatal infection due to bacterial, mycobacterial, invasive fungal, viral or other opportunistic pathogens has been reported in patients receiving TNF-blocking agents.  Among opportunistic infections, tuberculosis, histoplasmosis, aspergillosis, candidiasis, coccidioidomycosis, listeriosis, and pneumocystosis were the most common.  Treatment with certolizumab pegol should not be initiated in patients with an active infection, including clinically important localized infections.  Certolizumab pegol should be discontinued if a patient develops a serious infection or sepsis.  Patients who develop a new infection during treatment with certolizumab pegol should be closely monitored, undergo a prompt and complete diagnostic workup appropriate for immunocompromised patients, and appropriate antimicrobial therapy should be initiated.  Appropriate empiric antifungal therapy should also be considered while a diagnostic workup is performed for patients who develop a serious systemic illness and reside or travel in regions where mycoses are endemic.

Malignancies

During controlled and open-lab
'/>"/>

SOURCE UCB
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. New Cimzia® (certolizumab pegol) Data Show a Significant, Rapid Clinical Response and Reduced Disease Activity Among Diverse Patient Populations With Active Rheumatoid Arthritis (RA)
2. Rapid and Long-term Clinical Responses Observed in Rheumatoid Arthritis Patients Taking Cimzia® (certolizumab pegol), According to Data Being Highlighted During ACR Meeting
3. UCB Presents Growing Body of Long-term Efficacy Data at ACG 2010 Meeting to Further Support Treatment with Cimzia® (certolizumab pegol) in Multiple Patient Populations with Moderate to Severe Crohns Disease
4. Long-Term Data on Cimzia® (certolizumab pegol) for Moderate to Severe Crohns Disease to be Highlighted at ACG Meeting
5. New Data Show CIMZIA(R) (certolizumab pegol) Provides Sustained and Significant Symptom Improvement in Moderate to Severe Crohns Patients
6. CIMZIA(R) (Certolizumab Pegol) Provides Rapid and Sustained Relief from Signs and Symptoms of Rheumatoid Arthritis for Two Years
7. CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohns Disease Patients
8. CIMZIA(R) (certolizumab pegol) Reduces Intestinal Lesions and Induces Endoscopic Improvement in Crohns Patients
9. CIMZIA(R) (certolizumab pegol), Significantly Reduces Structural Damage and Rheumatoid Arthritis Signs & Symptoms for Up to One Year
10. New Subanalyses of the RE-LY Trial Showed Pradaxa Reduced Stroke Risk in Patients With Varying CHA2DS2-VASc Scores and Types of Non-Valvular Atrial Fibrillation
11. Prolia® (denosumab) Open-Label Extension Trial Showed Continued Increase in Bone Mineral Density Over Five Years of Treatment With Similar Safety Profile Observed in Pivotal Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... and SAN DIEGO , July 31, ... company Eisai Co., Ltd. (Headquarters: Tokyo ... and Halozyme Therapeutics, Inc. (Headquarters: San Diego, ... Torley , "NASDAQ: HALO") have signed a clinical collaboration ... ® , "eribulin") in combination with Halozyme,s investigational drug ...
(Date:7/30/2015)... -- Edwards Lifesciences Corporation (NYSE: EW ), the global ... today announced that Robert A. Ingram has retired ... an ardent champion for innovation in the lifesciences industry, and ... Edwards, board as we pursue our focused innovation strategy," said ... has provided a valuable perspective to our board, drawing on ...
(Date:7/30/2015)... 2015  ResMed Inc. (NYSE: RMD ) today ...  Revenue for the quarter was $453.1 million, a 9 ... 2014 (a 17 percent increase on a constant currency ... quarter ended June 30, 2014.  Diluted earnings per share ... ended June 30, 2014.  The results ...
Breaking Medicine Technology:Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 2Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 3Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 4Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 5Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 6ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 2ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 3ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 4ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 5ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 6ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 7ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 8ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 9ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 10ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 11ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 12ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 13ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 14ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 15ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 16
... Oct. 26 Sequoia Pharmaceuticals presented,positive results today ... protease inhibitor (PI). One study based on an ... of SPI-256 with HIV protease,provides a rationale for ... The second study conducted in healthy volunteers demonstrates,that ...
... Results of two Phase III studies affirmed the ... 25 Data from two Phase III studies,showed ... painful effects,of rheumatoid arthritis (RA) achieved significant improvements ... alone or in combination,with methotrexate compared with methotrexate ...
Cached Medicine Technology:Sequoia Pharmaceuticals Presents In Vitro and First-in-Human Data Supporting Further Development of SPI-256, a Novel Investigational Protease Inhibitor 2Sequoia Pharmaceuticals Presents In Vitro and First-in-Human Data Supporting Further Development of SPI-256, a Novel Investigational Protease Inhibitor 3Sequoia Pharmaceuticals Presents In Vitro and First-in-Human Data Supporting Further Development of SPI-256, a Novel Investigational Protease Inhibitor 4ACTEMRA (R) (tocilizumab) Significantly Reduced Signs and Symptoms of Rheumatoid Arthritis in Patients Who Failed Prior Treatments 2ACTEMRA (R) (tocilizumab) Significantly Reduced Signs and Symptoms of Rheumatoid Arthritis in Patients Who Failed Prior Treatments 3ACTEMRA (R) (tocilizumab) Significantly Reduced Signs and Symptoms of Rheumatoid Arthritis in Patients Who Failed Prior Treatments 4ACTEMRA (R) (tocilizumab) Significantly Reduced Signs and Symptoms of Rheumatoid Arthritis in Patients Who Failed Prior Treatments 5ACTEMRA (R) (tocilizumab) Significantly Reduced Signs and Symptoms of Rheumatoid Arthritis in Patients Who Failed Prior Treatments 6
(Date:7/31/2015)... GA (PRWEB) , ... July 31, 2015 , ... ... five new industry players to know in predictive health analytics , Jvion ... learning technologies. The firm creates predictive software that targets patient and population level ...
(Date:7/31/2015)... ... , ... The 2nd annual Ride to Fight On will start and end ... The Ride to Fight On is a cycling fundraiser that benefits the West Cancer ... and The University of Tennessee Health Science Center. A health and wellness festival featuring ...
(Date:7/31/2015)... ... 2015 , ... There’s no better way to enjoy the summer weather than ... the next meal, making July the most appropriate to be National Hot Dog Month. ... , Make the next cookout different than the ones in the past. Celebrate National ...
(Date:7/31/2015)... (PRWEB) , ... July 31, 2015 , ... ... communicate. Rally Insurance Group, Inc. has re-branded their social media profiles to better ... personal way for consumers to communicate, find information, share insights and opinions. The ...
(Date:7/31/2015)... ... , ... M3 USA MDLinx.com, source of the Smartest Doc Board Exam Prep ... , The additions of Gastroenterology, Pulmonology and Allergy/Immunology round out an already robust selection ... exam easy and painless. MDLinx offers thousands of board-exam style questions and exam-specific ...
Breaking Medicine News(10 mins):Health News:Jvion Showcased as Leader in the Predictive Analytic Market 2Health News:West Cancer Center Announces 2nd Annual Ride to Fight On 2Health News:West Cancer Center Announces 2nd Annual Ride to Fight On 3Health News:King Kullen Honors National Hot Dog and Blueberry Month 2Health News:King Kullen Honors National Hot Dog and Blueberry Month 3Health News:Rally Insurance Group, Inc. Connects to Customers Through Re-branded Social Media Profiles 2Health News:MDLinx Offers Three New Board Exam Prep Courses - Gastroenterology, Pulmonology and Allergy/Immunology 2Health News:MDLinx Offers Three New Board Exam Prep Courses - Gastroenterology, Pulmonology and Allergy/Immunology 3
... 16 The non-profit,organization Women in Government presented ... Association today at the John F.,Kennedy Center for ... Pennsylvania and nine other states for launching a ... Lieutenant Governor Knoll accepted the award on behalf ...
... New Rankings Show No City Is Allergy-Free, WASHINGTON, Nov. ... this fall, and some cities are much worse than others,according ... Asthma and,Allergy Foundation of America (AAFA). The Foundation recently announced ... was,crowned "the most challenging place to live with fall allergies" ...
... Inc.,(Nasdaq: HOLX ), a diversified diagnostic and medical ... of women, today announced,the Company will host a meeting ... the RSNA (Radiological Society of North America) trade,show in ... November 27, 2007, at McCormick,Place from 8:00 - 10:00 ...
... /PRNewswire/ Dilon Technologies, Inc. a,United States manufacturer and ... of Scott Yarde for the position of,Vice President ... Yarde joins Dilon to provide leadership in national ... track record with 25,years of sales, marketing and ...
... to Impose Stiffer Penalties, ... State Investigators, CLAREMONT, Calif., Nov. 16 ... action lawsuit against Health Net,Life Insurance Company, alleging ... insurance policies has needlessly placed the,lives of hundreds ...
... at six sites nationwide , FRIDAY, Nov. 16 ... the genetic and environmental factors that may cause autism, ... 2,700 children and their families from six areas in ... Development -- which researchers called the largest of its ...
Cached Medicine News:Health News:Austin Named the New 'Fall Allergy Capital' 2Health News:Hologic, Inc. to Host Investor Reception at the RSNA Trade Show 2Health News:Dilon Technologies Appoints New VP of Sales & Business Development 2Health News:Health Net Hit With Class Action Alleging Unfair Business Practices Over Retroactive Cancellations of Health Insurance Policies 2Health News:Health Net Hit With Class Action Alleging Unfair Business Practices Over Retroactive Cancellations of Health Insurance Policies 3Health News:Major U.S. Autism Study Gets Under Way 2
For the quantitative in vitro determination of apolipoprotein A-1 (apo A-1) in serum and plasma. For use as an aid if assessing the risk of coronary artery disease....
For the quantitative in vitro determination of Urea in serum, plasma and urine....
The XTRI method used on the Dimension clinical chemistry system is an in vitro diagnostic test intended for the quantitative determination of triglycerides in serum and plasma....
For the quantitative determination of Gamma Glutamyltransferase in serum or plasma...
Medicine Products: